The HMGCL Knockout A-549 Polyclonal Cells product is a population of human A-549 lung adenocarcinoma cells that have undergone CRISPR/Cas9-mediated disruption of the HMGCL gene, resulting in a heterogeneous pool of loss-of-function alleles. This polyclonal knockout format preserves the allelic diversity generated by genome editing, avoiding clonal selection biases and providing a more representative model for functional genomic studies compared to single-cell-derived clones. The cells are suitable for investigating HMGCL-dependent metabolic processes in a disease-relevant epithelial background.
The A-549 cell line was established from the lung adenocarcinoma of a 58-year-old male and displays an adherent epithelial morphology characteristic of alveolar type II pneumocytes. As a widely used model for lung cancer research and respiratory biology, A-549 cells recapitulate key features of transformed pulmonary epithelium, including altered metabolic pathways and growth-factor signaling, making them an ideal host for gene knockout studies targeting metabolic enzymes.
HMGCL encodes 3-hydroxy-3-methylglutaryl-CoA lyase, a mitochondrial enzyme that catalyzes the irreversible cleavage of HMG-CoA into acetoacetate and acetyl-CoA, the rate-limiting step in ketogenesis and the final reaction in leucine catabolism. Its activity is upregulated by PPAR?? and FOXA2 during fasting and by glucagon, while insulin suppresses its expression. HMGCL works in concert with HMGCS2, which supplies its substrate, and is interconnected with ACAT1, the mitochondrial trifunctional protein, and downstream effectors such as BDH1. Loss of HMGCL function leads to HMG-CoA accumulation, disruption of CoA homeostasis, and impaired production of ketone bodies, with consequences for energy metabolism in multiple tissues.
In A-549 cells, HMGCL knockout eliminates a critical node of lipid-derived energy production, forcing the cells to rewire their metabolism in a cancer context. This model enables dissection of how lung adenocarcinomas adapt to ketogenesis deficiency and may expose vulnerabilities related to branched-chain amino acid utilization. Moreover, the system recapitulates features of HMG-CoA lyase deficiency??a metabolic disorder characterized by hypoketotic hypoglycemia and organic aciduria??in a cancer-relevant epithelial setting, offering a tool to study disease mechanisms outside the traditional hepatic or fibroblast models.
The polyclonal knockout cells are compatible with a variety of downstream assays, including western blotting and RT-qPCR for confirmation of HMGCL ablation, LC-MS metabolite profiling to track changes in HMG-CoA and ketone bodies, and isotope-labeled leucine tracing to monitor metabolic flux. Functional studies such as mitochondrial respiration analysis (Seahorse), ketone body quantification, and cell viability assays under leucine deprivation can reveal compensatory pathways and synthetic lethal interactions. These applications support research into cancer metabolic reprogramming, HMG-CoA lyase deficiency pathogenesis, and metabolic drug target identification. For further technical inquiries, please contact Ascent Research.
